Fundraising Fox
Alveolus
8 employees on LinkedIn · 1 known investors
Find your way into Alveolus
Sign up to see every warm intro you have to Alveolus
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alveolus team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD. It serves patients with chronic and infectious respiratory conditions in the biotechnology and pharmaceutical space.
Founders & leadership
GM
Gaurav MehtaCEOGaurav Mehta is an MIT graduate with experience in global operations, having co-managed a $160M automated manufacturing facility at Alcon, and has founded ventures in healthcare technology that raised over $10M in funding.
Investors · 1
Related companies · 7
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
AlveoAlveo Technologies makes a palm-sized molecular diagnostic analyzer with preloaded test cartridges that deliver on-site pathogen results in under an hour, with results sent to a smartphone. It targets point-of-need infectious disease detection, including avian influenza testing for poultry farms and workers.
Nautilus BiotechnologyNautilus develops proteomics technology to unlock the complexity of the human proteome for biomedical research and diagnostics. The company targets pharmaceutical, biotechnology, academic, clinical, and government sectors with advanced protein quantification and analysis platforms.
Precision BioSciencesPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Alume BiosciencesAlume Biosciences develops nerve illumination technology for surgery, including bevonescein (ALM-488), an injectable peptide that makes nerves glow to help surgeons identify and preserve them during procedures such as head-and-neck and prostate surgery. The drug candidate is in Phase 3 clinical trials, with a planned FDA New Drug Application submission in 2026.
LatusLatus develops gene therapy research and development capabilities leveraging cell and gene therapy expertise. The company operates from Philadelphia and Boston, serving the biotechnology and therapeutics industry.
TELA BioOffers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.
Companies working in the same space as Alveolus.
Frequently asked questions
- What does Alveolus do?
- Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD. It serves patients with chronic and infectious respiratory conditions in the biotechnology and pharmaceutical space.
- Who founded Alveolus?
- Alveolus was founded by C Vivek Lal.
- Who are Alveolus's investors?
- Alveolus's investors include Lumira Ventures.